Candesartan Cilexetil in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM Added)

A study to evaluate the effect of Atacand on patients with heart failure with depressed left ventricular function

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Congestive Heart Failure Cardiovascular Diseases Heart Diseases Heart Failure

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Male or female aged 18 or above
Congestive Heart Failure with symptoms for more than 4 weeks before starting study
Provision of informed consent

Exclusion criteria

Current low blood pressure with symptoms
Liver disease considered significant by the study doctor
Pregnant or lactating females

Treatment and study plan

Candesartan

Drug

Other names: Atacand

Placebo

Drug

Primary outcomes

Cardiovascular mortality or hospitalisation due to congestive heart failure

Time frame: 2, 4, 6 weeks, 6 months, every 4 months thereafter until 24 months

Secondary outcomes

Cardiovascular mortality or hospitalisation for management of congestive heart failure, or non fatal MI

Time frame: 2, 4, 6 weeks, 6 months, every 4 months thereafter until 24 months

Sponsors and collaborators

Lead sponsor

AstraZeneca

Industry

Registry information

Official study title

Candesartan Cilexetil in Heart Failure Assessment of Reduction in Mortality and Morbidity. Clinical Study of Candesartan in Patients With Heart Failure and Depressed Left Ventricular Systolic Function

Important dates

Study start: 1999
Primary completion: 2003
Study completion: 2003
First posted: Mar 13, 2008
Registry last updated: Jan 25, 2011

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed